Want to see MLTX full AI Analyst Report?
MLTX Stock Chart & Stats
$15.56
$0.84(4.42%)
At close: 4:00 PM EDT
$15.56
$0.84(4.42%)
Day’s Range― - ―
52-Week Range$5.95 - $62.75
Previous CloseN/A
Volume138.32K
Average Volume (3M)1.19M
Market Cap
$1.29B
Enterprise Value$1.00K
Total Cash (Recent Filing)$537.03M
Total Debt (Recent Filing)$101.53M
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Nov 17, 2026EPS Estimate
-0.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.85
Shares Outstanding85,106,680
10 Day Avg. Volume1,034,690
30 Day Avg. Volume1,193,266
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)2.79
Price to Sales (P/S)0.00
P/FCF Ratio-4.33
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$38.00Price Target Upside144.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-3.52
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Positive Phase 3 PsA EfficacyThe positive Phase 3 psoriatic arthritis results broaden sonelokimab’s addressable market beyond hidradenitis suppurativa. Efficacy across primary and secondary endpoints, together with a consistent safety profile, supports a potentially differentiated late-stage product.
Durable HS Data And Regulatory PathDurable one-year efficacy and improvements in remission, pain and quality of life strengthen sonelokimab’s commercial case in hidradenitis suppurativa. A planned BLA filing creates a clearer regulatory path and could advance the asset toward commercialization.
Liquidity And Manufacturing ReadinessSubstantial liquidity supports continued late-stage development and reduces near-term execution pressure. Secured commercial manufacturing capacity also addresses a critical launch requirement, improving operational readiness if sonelokimab receives approval.
Bears Say
Pre-revenue And Widening LossesMoonLake has no product revenue and its losses have expanded sharply as clinical investment increases. Until approval and commercialization, earnings visibility remains limited, leaving the company dependent on successful development outcomes rather than recurring operating income.
High And Deteriorating Cash BurnThe accelerating operating cash deficit shows that MoonLake’s late-stage pipeline remains heavily cash consumptive. Sustained burn will require continued capital allocation and could reduce financial flexibility if development costs rise or regulatory timelines extend.
Funding Dependence And DilutionBecause MoonLake is pre-revenue, external financing remains central to funding operations. Equity issuance can dilute existing holders, while rising debt adds repayment obligations and may increase balance-sheet pressure if cash needs persist before commercialization.
MoonLake Immunotherapeutics News
MLTX FAQ
What was MoonLake Immunotherapeutics’s price range in the past 12 months?
MoonLake Immunotherapeutics lowest stock price was $5.95 and its highest was $62.75 in the past 12 months.
What is MoonLake Immunotherapeutics’s market cap?
MoonLake Immunotherapeutics’s market cap is $1.29B.
When is MoonLake Immunotherapeutics’s upcoming earnings report date?
MoonLake Immunotherapeutics’s upcoming earnings report date is Nov 17, 2026 which is in 73 days.
How were MoonLake Immunotherapeutics’s earnings last quarter?
MoonLake Immunotherapeutics released its earnings results on Aug 10, 2026. The company reported -$0.84 earnings per share for the quarter, beating the consensus estimate of -$0.909 by $0.069.
Is MoonLake Immunotherapeutics overvalued?
According to Wall Street analysts MoonLake Immunotherapeutics’s price is currently Undervalued.
Does MoonLake Immunotherapeutics pay dividends?
MoonLake Immunotherapeutics does not currently pay dividends.
What is MoonLake Immunotherapeutics’s EPS estimate?
MoonLake Immunotherapeutics’s EPS estimate is -0.79.
How many shares outstanding does MoonLake Immunotherapeutics have?
MoonLake Immunotherapeutics has 85,106,680 shares outstanding.
What happened to MoonLake Immunotherapeutics’s price movement after its last earnings report?
MoonLake Immunotherapeutics reported an EPS of -$0.84 in its last earnings report, beating expectations of -$0.909. Following the earnings report the stock price went down -5.093%.
Which hedge fund is a major shareholder of MoonLake Immunotherapeutics?
Currently, no hedge funds are holding shares in MLTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MoonLake Immunotherapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.00 (144.22% Upside)
$38.00 (144.22% Upside)
Blogger Sentiment
Bullish
MLTX Sentiment 94%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 456.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 3.0%
Last 30 Days ▲ 12.1%
Last 30 Days ▲ 12.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-74.86%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
24.75%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
MoonLake Immunotherapeutics
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.
MLTX Stock 12 Month Forecast
Average Price Target
$38.00
▲(144.22% Upside)
Technical Analysis
Ownership Overview
28.99% Insiders
1.78% Mutual Funds
54.81% Other Institutional Investors
13.58% Public Companies and
Individual Investors